- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Polyrizon begins usability study for intranasal allergy blocker | 1 | Investing.com | ||
| Do | Polyrizon Ltd.: Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX Allergy Blocker | 1 | GlobeNewswire (USA) | ||
| Do | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.01. | Polyrizon Ltd.: Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet | 2 | GlobeNewswire (USA) | ||
| 08.01. | Polyrizon Ltd.: Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX | 3 | GlobeNewswire (USA) | ||
| 05.01. | Positive Studiendaten zu Allergie-Blocker beflügeln Polyrizon-Aktie | 2 | Investing.com Deutsch | ||
| 05.01. | Polyrizon's nasal allergy blocker outperforms standard in lab study | 1 | Investing.com | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 05.01. | Polyrizon Ltd.: Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator | 1 | GlobeNewswire (USA) | ||
| 05.01. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.01. | Polyrizon submits pre-request to FDA for nasal spray against flu | 2 | Investing.com | ||
| 02.01. | Polyrizon Ltd.: As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated | 1 | GlobeNewswire (USA) | ||
| 29.12.25 | Polyrizon prüft Investitionen in Sachwerte - Aktie im Plus | 1 | Investing.com Deutsch | ||
| 29.12.25 | Polyrizon to explore investments in revenue-generating assets | 1 | Investing.com | ||
| 29.12.25 | Biotech-Unternehmen Polyrizon prüft Investitionen in ertragsstarke Sachwerte | 1 | Investing.com Deutsch | ||
| 29.12.25 | Polyrizon Ltd.: Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet | 235 | GlobeNewswire (Europe) | Company to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline Raanana, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ)... ► Artikel lesen | |
| 29.12.25 | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.12.25 | Polyrizon Ltd.: Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses | 1 | GlobeNewswire (USA) | ||
| 19.12.25 | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | Polyrizon Ltd.: Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program | 340 | GlobeNewswire (Europe) | Ra'anana, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 11.12.25 | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,890 | -1,31 % | Aktien Frankfurt Ausblick: Kleines Minus im Dax erwartet - Qiagen weiter stark | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt bleibt auch am Mittwoch im Korrekturmodus. Nachdem sich zuletzt die Unsicherheit wegen der Zoll-Politik von US-Präsident Donald Trump wieder verstärkt... ► Artikel lesen | |
| NOVAVAX | 7,894 | -3,25 % | NOVAVAX INC zeigt stabile Aufwärtskraft | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 15,600 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| BIOXXMED | 0,700 | +7,69 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,290 | +1,57 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| COSCIENS BIOPHARMA | 1,630 | +7,24 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| XOMA ROYALTY | 21,600 | -0,92 % | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,030 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 0,780 | -4,46 % | Oragenics ändert "At-the-Market"-Vertriebsvereinbarung mit Dawson James Securities | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment | Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half... ► Artikel lesen | |
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 10.10.2025 | The following instruments on XETRA do have their last trading day on 10.10.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 10.10.2025ISIN NameDE000DB9U2Y9 DT.BANK IS. 20/25US44891CBN20... ► Artikel lesen | |
| SERES THERAPEUTICS | 12,400 | -3,28 % | Seres Therapeutics, Inc.: Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 | CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria... ► Artikel lesen | |
| EDESA BIOTECH | 1,390 | 0,00 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal Year 2025 Results | TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen |
POLYRIZON LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,000 Euro und damit +2,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.